Antimycobacterial Agents Differ with Respect to Their Bacteriostatic versus Bactericidal Activities in Relation to Time of Exposure, Mycobacterial Growth Phase, and Their Use in Combination
Open Access
- 1 June 2005
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (6) , 2387-2398
- https://doi.org/10.1128/aac.49.6.2387-2398.2005
Abstract
A number of antimycobacterial agents were evaluated with respect to their bacteriostatic activity (growth inhibition) versus the bactericidal activity against a clinical isolate of Mycobacterium avium ( Mycobacterium avium complex [MAC] strain 101) in relation to the time of exposure and the growth phase of the mycobacteria. In terms of growth inhibition the MAC in the active phase of growth was susceptible to clarithromycin, ethambutol, rifampin, amikacin, and the quinolones moxifloxacin, ciprofloxacin, and sparfloxacin. In terms of bactericidal activity in relation to the time of exposure these agents differed substantially with respect to the killing rate. An initial high killing capacity at low concentration was observed for amikacin, which in this respect was superior to the other agents. The bactericidal activity of clarithromycin and ethambutol was only seen at relatively high concentrations and increased with time. Killing by rifampin was concentration dependent as well as time dependent. The bactericidal activity of moxifloxacin was marginally dependent on the concentration or the time of exposure. The activity of clarithromycin in combination with ethambutol was not significantly enhanced compared to single-agent exposure. Only an additive effect was observed. The addition of rifampin or moxifloxacin as a third agent only marginally effected increased killing of MAC. However, by addition of amikacin the activity of the clarithromycin-ethambutol combination was significantly improved. The combination of amikacin and amoxicillin-clavulanic acid exhibited synergistic antimycobacterial activity. Towards MAC at low growth rates, only the quinolones exhibited a bactericidal effect.Keywords
This publication has 49 references indexed in Scilit:
- Recent developments in the treatment of tuberculosisExpert Opinion on Investigational Drugs, 2003
- Multisite Reproducibility of Results Obtained by Two Broth Dilution Methods for Susceptibility Testing of Mycobacterium avium ComplexJournal of Clinical Microbiology, 2003
- A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individualsAIDS, 1998
- Does In Vitro Susceptibility to Rifabutin and Ethambutol Predict the Response to Treatment ofMycobacterium aviumComplex Bacteremia with Rifabutin, Ethambutol, and Clarithromycin?Clinical Infectious Diseases, 1998
- A Randomized Evaluation of Ethambutol for Prevention of Relapse and Drug Resistance during Treatment ofMycobacterium aviumComplex Bacteremia with Clarithromycin‐Based Combination TherapyThe Journal of Infectious Diseases, 1997
- The Role of Advanced Generation Macrolides in the Prophylaxis and Treatment of Mycobacterium avium Complex (MAC) InfectionsDrugs, 1997
- Prevention of the Selection of Clarithromycin-Resistant Mycobacterium avium-intracellulare ComplexDrugs, 1997
- Effect of Ethambutol on Emergence of Clarithromycin-Resistant Mycobacterium avium Complex in the Beige Mouse ModelThe Journal of Infectious Diseases, 1996
- In-vitro evaluation of clarithromycin, temafloxacin, and ethambutol in combination against Mycobacterium avium complexJournal of Antimicrobial Chemotherapy, 1993
- The in-vitro bactericidal activities of combinations of antimicrobial agents against clinical isolates of Mycobacterium avium-intracellulareJournal of Antimicrobial Chemotherapy, 1992